Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on February 1, 2021, covering events occurring on January 29, 2021. The filing addresses Item 5.02 regarding the execution of amended and restated employment agreements with three key executive officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
On January 29, 2021, the Company entered into new employment agreements with:
- Eric D. Shaff (President and CEO)
- Thomas J. DesRosier (Chief Legal Officer, EVP, and Secretary)
- Matthew R. Henn, Ph.D. (EVP and Chief Scientific Officer)
These agreements update severance and change-in-control provisions for the named executives.
Management Commentary and Compensation Details
The amended agreements outline specific severance benefits triggered by termination without cause or resignation for good reason:
- Eric D. Shaff:
- Standard Termination: 18 months of base salary, up to 18 months of COBRA coverage, and immediate vesting of time-based equity awards that would have vested within 12 months of termination.
- Change in Control (within 60 days prior or 12 months following): Accelerated vesting of time-based equity awards, 18 months of base salary, up to 18 months of COBRA coverage, and a lump sum cash payment equal to 1.5 times the target bonus for the year of termination.
- Thomas J. DesRosier and Matthew R. Henn:
- Standard Termination: 12 months of base salary and up to 12 months of COBRA coverage.
- Change in Control (within 60 days prior or 12 months following): Accelerated vesting of time-based equity awards, 12 months of base salary, up to 12 months of COBRA coverage, and a lump sum cash payment equal to 1.0 times the target bonus for the year of termination.
Receipt of these payments is generally contingent upon the executive executing a general release of claims and complying with restrictive covenants.
Investor Verification Checklist
- Review the full text of Exhibits 10.1, 10.2, and 10.3 attached to the filing for complete legal terms.
- Verify the current target bonus amounts for each executive to calculate potential lump-sum payouts.
- Assess the impact of these agreements on the Company's cash reserves in the event of a change in control.
- Confirm the vesting schedules of existing time-based equity awards for the named executives.